Vineet Labs revenue jumps, but tax charge cuts profit by 92%
Expenses outpaced revenue growth and the tax rate swung sharply, while operating margin remained below the healthcare peer median.
Filed 13 Nov 2026, 13:21 IST · Vineet Laboratories Ltd (VINEETLAB)
Key takeaways
- Standalone revenue rose 36.48% sequentially to Rs 14.18 cr, but expenses grew faster at 45.70%, cutting operating margin by 5.30 percentage points.
- Net profit fell 92.05% sequentially to Rs 0.12 cr as the tax rate swung from -92.73% to 91.69%, despite a 75.95% rise in profit before tax.
- Operating margin at 16.36% was 5.28 percentage points below the 21.64% median for 103 reported healthcare peers.
Price around the results
Revenue recovered, but costs grew faster
Standalone revenue increased 36.48% sequentially to Rs 14.18 cr, while operating profit rose only 3.11% to Rs 2.32 cr. Expenses grew 45.70%, outpacing revenue growth and reducing operating margin to 16.36% from 21.66% in Q1FY27. Depreciation was unchanged at Rs 0.60 cr, while interest expense fell 64.95% to Rs 0.34 cr.
Tax swing overwhelmed the pre-tax improvement
Profit before tax rose 75.95% sequentially to Rs 1.39 cr, but the tax rate moved up 184.42 percentage points to 91.69% from a negative 92.73% in the previous quarter. That tax charge reduced net profit by 92.05% to Rs 0.12 cr and EPS to Rs 0.06. Other income contributed only 1.44% of pre-tax profit, so it was not a material support for earnings quality.
Margin remains below peers after a one-quarter rebound
Operating margin improved from 13.21% in Q4FY26 to 21.66% in Q1FY27 before falling to 16.36% in Q2FY27, so the latest quarter marks a sequential reversal rather than a third straight decline. The margin was 5.28 percentage points below the 21.64% median of 103 healthcare companies that had reported.
Initial stock reaction was limited
The stock opened 1.64% higher but was down 0.32% at the measured reaction point, with relative performance of 0.30%. Trading volume was 0.32 times the reference level.
Q2FY27 at a glance
Standalone figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q2FY27 | Q1FY27 | QoQ |
|---|---|---|---|
| Revenue | ₹14 cr | ₹10 cr | +36.48% |
| Other income | ₹0 cr | ₹0 cr | -81.82% |
| Expenses | ₹12 cr | ₹8 cr | +45.70% |
| Operating profit | ₹2 cr | ₹2 cr | +3.11% |
| Operating margin (%) | 16.36% | 21.66% | — |
| Interest | ₹0 cr | ₹1 cr | -64.95% |
| Depreciation | ₹1 cr | ₹1 cr | +0.00% |
| Profit before tax | ₹1 cr | ₹1 cr | +75.95% |
| Tax | ₹1 cr | ₹-1 cr | — |
| Net profit | ₹0 cr | ₹2 cr | -92.05% |
| EPS (₹) | ₹0.06 | ₹0.73 | -91.78% |
Operating margin of 16.36% compares with a Healthcare sector median of 21.64% across 103 peers that have reported Q2FY27.
How the stock reacted
| Window | Stock | vs NIFTY |
|---|---|---|
| Results day | -0.32% | +0.30% |
Volume on the results session was 0.32× its 20-day average.
What to watch
- Whether operating margin recovers from 16.36% after the 5.30-percentage-point sequential decline.
- Whether the tax rate moves down from 91.69% after the 184.42-percentage-point sequential swing.
- Whether expenses continue to grow faster than revenue after rising 45.70% versus revenue growth of 36.48%.